Mostrando 2 resultados de: 2
Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study
ArticleAbstract: Background: Several pieces of evidence have shown the neurotrophic effect of erythropoietin (EPO) anPalabras claves:Clinical trial, erythropoietin, human-recombinant erythropoietin, spinocerebellar ataxia type 2Autores:Almaguer Gotay D., Amaro-González D., Aymed-García J., Batista-Nuñez M., Canales-Ochoa N., Carmen Elena Viada, Columbié Ximelis J., Crombet-Ramos T., Estupiñán Rodriguez A., García-García I., García-Rodriguez J.C., Hernández Casaña P., Jiménez-Rodríguez D., Labrada Aguilera P.E., Medrano Montero J., Ortega-Sanchez R., Padrón-Estupiñan M.d.C., Peña Acosta A., Rodríguez-Labrada R., Rodriguez-Obaya T., Santos-Morales O., Silva Ricardo Y., Torres Vega R., Tribin Rivero K., Valenzuela-Silva C.M., Valle Cabrera R., Vazquez-Mojena Y., Velazquez-Perez L.Fuentes:scopusOral zinc sulphate supplementation for six months in SCA2 patients: A randomized, double-blind, placebo-controlled trial
ArticleAbstract: Cuban patients with Spinocerebellar Ataxia type 2 (SCA2) have reduced concentrations of zinc in seruPalabras claves:Clinical trial, SCA2, Spinocerebellar ataxia 2, Zn supplementationAutores:Aguilera-Rodríguez R., Almaguer Mederos L.E., Batista I.H., Canales-Ochoa N., García-Rodriguez J.C., Gotay D.A., Laffita Mesa J.M., Novas A.J., Orestes Darío López-Hernández, Polanco I.D., Porto-Verdecia M., Pupo N.R., Rodríguez-Chanfrau J.E., Rodríguez-Díaz J.C., Rodríguez-Labrada R., Sánchez-Cruz G., Triana C.G., Velazquez-Perez L.Fuentes:googlescopus